We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 14. | 장 마감 후 (AMC) | — | — | — | $0 | — | 예정 |
| FY2026 Q3 | 2025. 03. 31. | 시각 미정 | — | $-0.84 | — | — | $0 | 보고됨 |
| FY2026 Q2 | 2024. 12. 31. | 시각 미정 | — | $-0.45 | — | — | $0 |
Consensus PT $24.33 · 6 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 13. | Evercore ISI Group | — | 커버리지 개시 | — → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 03. 10. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2026 Q1 | 2024. 09. 30. | 시각 미정 | — | $-0.18 | — | — | $0 | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Stored first · Google News · Yahoo Finance (English)
Benitec Biopharma Announces Board Changes and New Director - TipRanks
Benitec Biopharma Announces Board Changes and New Director TipRanks
Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma - CFO Megan Boston Resigns From Board Effective May 22, 2026 TradingView
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 - marketscreener.com
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 marketscreener.com
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 Stock Titan